Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Natural Killer Cell Dysfunction In Human Bladder Cancer Is Caused By Tissue-Specific Suppression of SLAMF6 Signaling.
Farkas AM, Youssef D, Tran MA, Balan S, Newman JH, Audenet F, Anastos H, Velazquez LG, Peros A, Ananthanarayanan A, Daza J, Gonzalez-Gugel E, Sadanala K, Theorell J, Galsky MD, Horowitz A, Sfakianos JP, Bhardwaj N. Farkas AM, et al. Among authors: galsky md. bioRxiv [Preprint]. 2024 Sep 19:2024.04.30.591366. doi: 10.1101/2024.04.30.591366. bioRxiv. 2024. PMID: 38746459 Free PMC article. Preprint.
HLA-E and NKG2A Mediate Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer.
Ranti D, Yu H, Wang YA, Bieber C, Strandgaard T, Salomé B, Houghton S, Kim J, Ravichandran H, Okulate I, Merritt E, Bang S, Demetriou A, Li Z, Lindskrog SV, Ruan DF, Daza J, Rai R, Hegewisch-Solloa E, Mace EM, Fernandez-Rodriguez R, Izadmehr S, Doherty G, Narasimhan A, Farkas AM, Cruz-Encarnacion P, Shroff S, Patel F, Tran M, Park SJ, Qi J, Patel M, Geanon D, Kelly G, de Real RM, Lee B, Nie K, Miake-Iye S, Angeliadis K, Radkevich E, Thin TH, Garcia-Barros M, Brown H, Martin B, Mateo A, Soto A, Sussman R, Shiwlani S, Francisco-Simon S, Beaumont KG, Hu Y, Wang YC, Wang L, Sebra RP, Smith S, Skobe M, Clancy-Thompson E, Palmer D, Hammond S, Hopkins BD, Wiklund P, Zhu J, Bravo-Cordero JJ, Brody R, Hopkins B, Chen Z, Kim-Schulze S, Dyrskjøt L, Elemento O, Tocheva A, Song WM, Bhardwaj N, Galsky MD, Sfakianos JP, Horowitz A. Ranti D, et al. Among authors: galsky md. bioRxiv [Preprint]. 2024 Sep 3:2024.09.02.610816. doi: 10.1101/2024.09.02.610816. bioRxiv. 2024. PMID: 39282294 Free PMC article. Preprint.
Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis.
Izadmehr S, Fernandez-Hernandez H, Wiredja D, Kirschenbaum A, Lee-Poturalski C, Tavassoli P, Yao S, Schlatzer D, Hoon D, Difeo A, Levine AC, Mosquera JM, Galsky MD, Cordon-Cardo C, Narla G. Izadmehr S, et al. Among authors: galsky md. bioRxiv [Preprint]. 2024 Feb 1:2024.01.30.577982. doi: 10.1101/2024.01.30.577982. bioRxiv. 2024. PMID: 38352401 Free PMC article. Preprint.
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.
Yoo SK, Fitzgerald CW, Cho BA, Fitzgerald BG, Han C, Koh ES, Pandey A, Sfreddo H, Crowley F, Korostin MR, Debnath N, Leyfman Y, Valero C, Lee M, Vos JL, Lee AS, Zhao K, Lam S, Olumuyide E, Kuo F, Wilson EA, Hamon P, Hennequin C, Saffern M, Vuong L, Hakimi AA, Brown B, Merad M, Gnjatic S, Bhardwaj N, Galsky MD, Schadt EE, Samstein RM, Marron TU, Gönen M, Morris LGT, Chowell D. Yoo SK, et al. Among authors: galsky md. Nat Med. 2025 Jan 6. doi: 10.1038/s41591-024-03398-5. Online ahead of print. Nat Med. 2025. PMID: 39762425
Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials.
Blanter J, Van Hyfte G, Ahmad M, Xu S, Hapanowicz O, Fazilov G, Lu A, Lucas N, Wu K, Shelton G, DeMerchant M, Lachowicz M, Kier M, Werner M, Eder JP, Galsky MD, Marron TU, Smith CB, LoRusso PM, Hofstatter E, Doroshow DB. Blanter J, et al. Among authors: galsky md. JCO Oncol Pract. 2024 Dec 11:OP2400293. doi: 10.1200/OP.24.00293. Online ahead of print. JCO Oncol Pract. 2024. PMID: 39661920
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.
Rosenberg JE, Galsky MD, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, van der Heijden MS, Dreicer R, Durán I, Castellano D, Drakaki A, Retz M, Sridhar SS, Grivas P, Yu EY, O'Donnell PH, Burris HA, Mariathasan S, Shi Y, Goluboff E, Bajorin D. Rosenberg JE, et al. Among authors: galsky md. ESMO Open. 2024 Dec;9(12):103972. doi: 10.1016/j.esmoop.2024.103972. Epub 2024 Dec 5. ESMO Open. 2024. PMID: 39642637 Free PMC article. Clinical Trial.
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade.
Hamidi H, Senbabaoglu Y, Beig N, Roels J, Manuel C, Guan X, Koeppen H, Assaf ZJ, Nabet BY, Waddell A, Yuen K, Maund S, Sokol E, Giltnane JM, Schedlbauer A, Fuentes E, Cowan JD, Kadel EE 3rd, Degaonkar V, Andreev-Drakhlin A, Williams P, Carter C, Gupta S, Steinberg E, Loriot Y, Bellmunt J, Grivas P, Rosenberg J, van der Heijden MS, Galsky MD, Powles T, Mariathasan S, Banchereau R. Hamidi H, et al. Among authors: galsky md. Cancer Cell. 2024 Dec 9;42(12):2098-2112.e4. doi: 10.1016/j.ccell.2024.10.016. Epub 2024 Nov 21. Cancer Cell. 2024. PMID: 39577421
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
Hamilton E, Galsky MD, Ochsenreither S, Del Conte G, Martín M, De Miguel MJ, Yu EY, Williams A, Gion M, Tan AR, Agrawal L, Rutten A, Machiels JP, Cresta S, Debruyne PR, Hennequin A, Moreno V, Minchom A, Valdes-Albini F, Petrylak D, Li L, Tsuchihashi Z, Suto F, Cheng FC, Kandil M, Barrios D, Hurvitz S. Hamilton E, et al. Among authors: galsky md. Clin Cancer Res. 2024 Dec 16;30(24):5548-5558. doi: 10.1158/1078-0432.CCR-24-1513. Clin Cancer Res. 2024. PMID: 39405343 Free PMC article. Clinical Trial.
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.
Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Agerbaek M, Jha G, Stenner F, Ye D, Giudici F, Dutta S, Askelson M, Nasroulah F, Zhang J, Brophy L, Bajorin DF. Galsky MD, et al. J Clin Oncol. 2025 Jan;43(1):15-21. doi: 10.1200/JCO.24.00340. Epub 2024 Oct 11. J Clin Oncol. 2025. PMID: 39393026 Free PMC article. Clinical Trial.
Tumor Characteristics Associated With Preoperatively Detectable Tumor-Informed Circulating Tumor DNA in Patients With Renal Masses Suspicious for Renal Cell Carcinoma.
Ben-David R, Alerasool P, Kalola H, Tillu N, Almoflihi M, Tsao CK, Galsky MD, Sfakianos JP, Wiklund P, Waingankar N, Mehrazin R. Ben-David R, et al. Among authors: galsky md. JCO Precis Oncol. 2024 Sep;8:e2400281. doi: 10.1200/PO.24.00281. Epub 2024 Sep 30. JCO Precis Oncol. 2024. PMID: 39348609
383 results